Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: An exploratory analysis

Journal of Geriatric Oncology

Volumn 5, Issue 4, 2014, Pages 368-375

  Ward, Peter ^a   Hecht, J Randolph ^a   Wang, He Jing ^a   Dichmann, Richard ^b   Liem, Andre K D ^c   Chan, David ^d   Patel, Ravi ^e   Hu, Edward H L ^f   Tchekmedyian, Neres S ^c   Wainberg, Zev A ^a   Naeim, Arash ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 220 S Palisade Dr Suite 204   (United States)

^c Pacific Shores Medical Group   (United States)

^d TORI   (United States)

^e TORI   (United States)

^f TORI   (United States)

Author keywords

Colon cancer; Colorectal cancer; Elderly; Frail; Metastatic; Performance status; Physical function; Quality of life; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; AGED; AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; FRAIL ELDERLY; HUMAN; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ONSET AGE; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QUALITY OF LIFE; SELF CONCEPT; TREATMENT DURATION; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GERIATRIC ASSESSMENT; HEALTH STATUS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALIFORNIA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84930928501     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2014.05.002     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics CA Cancer J Clin 2010, 60(5):277-300. [Epub 2010/07/09].
2. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067. [Epub 1999/12/30].
3. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65years of age or older in cancer clinical trials. J Clin Oncol 2003, 21(7):1383-1389. [Epub 2003/03/29].
4. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947. [Epub 2000/08/16].
5. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914. [Epub 2000/09/28].
6. Sargent D.J., Kohne C.H., Sanoff H.K., Bot B.M., Seymour M.T., de Gramont A., et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009, 27(12):1948-1955. [Epub 2009/03/04].
7. Hurwitz H.I., Saltz L.B., Van Cutsem E., Cassidy J., Wiedemann J., Sirzen F., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011, 29(13):1757-1764. [Epub 2011/03/23].
8. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23(16):3697-3705. [Epub 2005/03/02].
9. Kozloff M.F., Berlin J., Flynn P.J., Kabbinavar F., Ashby M., Dong W., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339. [Epub 2010/08/25].
10. Feliu J., Safont M.J., Salud A., Losa F., Garcia-Giron C., Bosch C., et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010, 102(10):1468-1473. [Epub 2010/04/29].
11. Sanoff H.K., Goldberg R.M., Pignone M.P. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer 2007, 6(10):700-709. [Epub 2007/11/28].
12. Extermann M. Geriatric assessment with focus on instrument selectivity for outcomes. Cancer J 2005, 11(6):474-480. [Epub 2006/01/06].
13. Naeim A., Ward P.R., Wang H.J., Dichman R., Liem A.K.D., Chan D., et al. Phase II study of front-line capecitabine and bevacizumab in frail and elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2013, 4(4):302-309. [Epub 2013/06/10].
14. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383. [Epub 1987/01/01].
15. Katz S., Ford A.B., Moskowitz R.W., Jackson B.A., Jaffe M.W. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963, 185:914-919. [Epub 1963/09/21].
16. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9(3):179-186. [Epub 1969/01/01].
17. Podsiadlo D., Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39(2):142-148. [Epub 1991/02/01].
18. Pirozzo S., Papinczak T., Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003, 327(7421):967. [Epub 2003/10/25].
19. Ward W.L., Hahn E.A., Mo F., Hernandez L., Tulsky D.S., Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999, 8(3):181-195. [Epub 1999/09/03].
20. Yost K.J., Cella D., Chawla A., Holmgren E., Eton D.T., Ayanian J.Z., et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol 2005, 58(12):1241-1251. [Epub 2005/11/18].
21. The EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(3):199-208. [Epub 1990/11/05].
22. Moore A.A., Siu A.L. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. Am J Med 1996, 100(4):438-443. [Epub 1996/04/01].
23. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3):176-181.
24. Puthillath A., Mashtare T., Wilding G., Khushalani N., Steinbrenner L., Ross M.E., et al. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 2009, 71(3):242-248. [Epub 2008/12/17].
25. Viccaro L.J., Perera S., Studenski S.A. Is timed up and go better than gait speed in predicting health, function, and falls in older adults?. J Am Geriatr Soc 2011 May, 59(5):887-892.
26. Bischoff H.A., Stähelin H.B., Monsch A.U., Iversen M.D., Weyh A., von Dechend M. Identifying a cut-off point for normal mobility: a comparison of the timed 'and go' test in community-dwelling and institutionalised elderly women. Age Ageing May 2003, 32(3):315-320.
27. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30. [Epub 2003/12/11].
28. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. J Clin Oncol 2010, 28:15s. [Suppl.; abstr 9001].